[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100577446":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":26,"centralContacts":31,"locations":38,"responsibleParty":58,"collaborators":62,"id":65,"slug":66,"hasResults":67,"nctId":68,"briefTitle":69,"officialTitle":70,"acronym":26,"eligibilityCriteria":71,"healthyVolunteers":67,"sex":72,"minAge":73,"maxAge":74,"enrollmentInfo":75,"targetDuration":26,"studyType":78,"phases":79,"briefSummary":81,"conditions":82,"keywords":26,"overallStatus":41,"whyStopped":26,"lastUpdateSubmitDate":84,"lastUpdatePostDateStruct":85,"startDateStruct":88,"completionDateStruct":90,"leadSponsor":92,"locationsCount":93},{"fullName":5,"class":6},"Al-Mustafa University College","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"intralesional ciprofloxacin","EXPERIMENTAL","Intralesional ciprofloxacin (2 mg\u002Fml, 100 ml, Ciproxin®, Bayer Schering pharma AG, Germany), each lesion was injected based on lesion size (2 mg\u002Fcm2). The infiltration of intralesional dose was given once weekly for up to 6 weeks. Treatment will be stopped in patients cured before 6 weeks of treatment, and patients were only asked to come for lesion assessment. A fine insulin needle was used to infiltrate the lesion.\n\nThe lesion was thoroughly infiltrated with the drug solution until the base was completely blanched. Depending on the lesion size, the amount of solution required ranged from 0.2 to 4.0 ml per lesion. No local anesthesia was added. The solutions were injected intralesionally and not subcutaneously.",[13],"Drug: Ciprofloxacin (BAYO9867)",{"label":15,"type":16,"description":17,"interventionNames":18},"intralesional sodium stibogluconate","ACTIVE_COMPARATOR","Intralesional sodium stibogluconate (100 mg\u002Fml, 100 ml vial, Pentostam®, GlaxoSmithKline, UK), each lesion was injected based on lesion size (1 mg\u002Fcm2).\n\nThe infiltration of intralesional dose was given once weekly for up to 6 weeks. Treatment will be stopped in patients cured before 6 weeks of treatment, and patients were only asked to come for lesion assessment. A fine insulin needle was used to infiltrate the lesion.\n\nThe lesion was thoroughly infiltrated with the drug solution until the base was completely blanched. Depending on the lesion size, the amount of solution required ranged from 0.2 to 4.0 ml per lesion. No local anesthesia was added. The solutions were injected intralesionally and not subcutaneously.",[19],"Drug: sodium stibogluconate (Pentostam)",[21,27],{"type":22,"name":23,"description":24,"armGroupLabels":25,"otherNames":26},"DRUG","Ciprofloxacin (BAYO9867)","Intralesional ciprofloxacin (2 mg\u002Fml, 100 ml, Ciproxin®, Bayer Schering pharma AG, Germany), each lesion was injected based on lesion size (2 mg\u002Fcm2).",[9],null,{"type":22,"name":28,"description":29,"armGroupLabels":30,"otherNames":26},"sodium stibogluconate (Pentostam)","Intralesional sodium stibogluconate (100 mg\u002Fml, 100 ml vial, Pentostam®, GlaxoSmithKline, UK), each lesion was injected based on lesion size (1 mg\u002Fcm2)",[15],[32],{"name":33,"role":34,"phone":35,"phoneExt":36,"email":37},"Hayder Adnan Fawzi, PhD","CONTACT","009647800106177","+ 964","haider-pharm@almustafauniversity.edu.iq",[39],{"facility":40,"status":41,"city":42,"state":26,"zip":43,"country":44,"countryCode":45,"cosmosGeoPoint":46,"geoPoint":51,"contacts":52},"Mustansiriyah University","RECRUITING","Baghdad","10047","Iraq","IQ",{"type":47,"coordinates":48},"Point",[49,50],44.40088,33.34058,{"lat":50,"lon":49},[53],{"name":54,"role":34,"phone":55,"phoneExt":56,"email":57},"Kadhim Ali Kadhim, PhD","7700365655","+964","Pharm.drkaka75@uomustansiriyah.edu.iq",{"type":59,"investigatorFullName":60,"investigatorTitle":61,"investigatorAffiliation":5,"oldNameTitle":26,"oldOrganization":26},"PRINCIPAL_INVESTIGATOR","Hayder Adnan Fawzi","Ass Prof",[63],{"name":64,"class":6},"Al-Mustansiriyah University","100577446","phase-2-ciprofloxacin-intralesional-injection-for-the-treatment-of-cutaneous-leishmaniasis-compared-to-sodium-stibogluconate-100577446",false,"NCT06798402","Ciprofloxacin Intralesional Injection for the Treatment of Cutaneous Leishmaniasis Compared to Sodium Stibogluconate","Effectiveness of Ciprofloxacin Intralesional Injection in the Treatment of Cutaneous Leishmaniasis Compared to Sodium Stibogluconate: a Parallel Groups Comparative Trial","Inclusion Criteria:\n\n* Patients with single or multiple (less than seven lesions) lesions of cutaneous leishmaniasis\n\nExclusion Criteria:\n\n* Patients who received anti-leishmaniasis treatment locally or systemically for the last month before this study\n* patients on prolonged corticosteroid therapy.","ALL","18 Years","80 Years",{"count":76,"type":77},80,"ESTIMATED","INTERVENTIONAL",[80],"PHASE2","The Aim of the trial to evaluate the effectiveness of intralesional ciprofloxacin 0.2% solution as a local injection in treating cutaneous leishmaniasis and compare its effect with intralesional sodium stibogluconate (SSG) 10% intravenous solution in cutaneous leishmaniasis as a local injection.\n\nIn a randomized parallel groups clinical trial, patients were divided into two groups based on therapeutic regimen: 1) intralesional sodium stibogluconate weekly injection and 2) intralesional ciprofloxacin injection. Each lesion was considered a case in the final analysis. Each lesion will be followed up for 90 days (censor endpoint) or until the lesions are cured.",[83],"Cutaneous Leishmaniasis","2025-09-29",{"date":86,"type":87},"2025-09-30","ACTUAL",{"date":89,"type":87},"2025-02-07",{"date":91,"type":77},"2025-11-01",{"name":5,"class":6},1]